Duravent PE

Product NDC
28595-905
11-digit product format
285950905
Labeler code
28595
Product ID
28595-905_a8aa7148-a219-4c68-895c-b3753d730526
Type
HUMAN OTC DRUG
Nonproprietary name
GUAIFENESIN and PHENYLEPHRINE HYDROCHLORIDE
Dosage form
TABLET
Route
ORAL
Labeler
Allegis Pharmaceuticals, LLC
Application
part341
Marketing category
OTC MONOGRAPH FINAL
Marketing start
2014-02-27
Marketing end
0000-00-00
Substance
GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
Active strength
395 mg/1; mg/1
NDC exclude flag
No
Listing certified through
2019-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct28595-905DDiscontinued by firm2026-10-05
excluded packagepackage28595-90528595-905-60DDiscontinued by firm2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 24 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage28595-905-60d630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage28595-905-60f5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproduct2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage28595-905-602ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproducta1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage28595-905-60a1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage28595-905-60cfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage28595-905-60cdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproduct302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage28595-905-60302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproducted331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage28595-905-60ed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproduct0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage28595-905-600efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage28595-905-60ad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproduct367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage28595-905-60367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproduct557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage28595-905-60557ba5c1ecfa…9c80585c8c6e…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
28595-905-60EA - Each28595-905700693d8-7089-496a-b3f5-664b8456a49b12014-04-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
GUAIFENESINACTIVE INGREDIENT495W7451VQDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
PHENYLEPHRINE HYDROCHLORIDEACTIVE INGREDIENT04JA59TNSJDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
GUAIFENESINACTIVE MOIETY495W7451VQDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
PHENYLEPHRINEACTIVE MOIETY1WS297W6MVDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61UDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
CROSCARMELLOSE SODIUMINACTIVE INGREDIENTM28OL1HH48DURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBDDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
HYPROMELLOSESINACTIVE INGREDIENT3NXW29V3WODURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
MALTODEXTRININACTIVE INGREDIENT7CVR7L4A2DDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
POVIDONESINACTIVE INGREDIENTFZ989GH94EDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU4DURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1
STEARIC ACIDINACTIVE INGREDIENT4ELV7Z65APDURAVENT PE (GUAIFENESIN AND PHENYLEPHRINE HYDROCHLORIDE) TABLET [ALLEGIS PHARMACEUTICALS, LLC]1